The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol

What's New at The Body

HIV/AIDS News You Can Use

October 11, 2001

Tenofovir Facts and Access

One of the most eagerly awaited drugs is tenofovir disoproxil fumarate (Viread). Tim Horn looks at the latest studies in CRIA Update.

In many countries, physicians may now provide tenofovir at no cost for people with HIV/AIDS. This once-a-day medication is meant for people whose previous anti-HIV medications have failed.

To find out more about tenofovir, browse through The Body's rich collection of articles.

Resistance Testing: Frequently Asked Questions

Just when everyone starts getting used to viral load tests, with all their confusing "logs" and "copies" and "undetectable levels," another family of lab tests with its own bewildering lingo arrives on the scene. Tim Horn explains drug-resistance tests and why they are important in CRIA Update.

Several recent studies show the complexities involved in interpreting the results of resistance tests and make it clear that some fine-tuning is still required. Ben Cheng looks at the data for resistance testing in CRIA Update.

HIV University for Women

L.A. women have a new weapon to fight HIV -- it's called knowledge. Cathy Olufs writes about Women Alive's second annual HIV University learning program for women.

Quality of Life Survey

CRIA Update surveyed its readers on their quality of life. Read the interesting results.

Greed and HIV

Some doctors and pharmaceutical companies are profiteering from one of the most lucrative illnesses ever to hit humankind. For the details on exactly how people are getting rich off HIV, click here.

New World AIDS Campaign

This year's World AIDS Campaign will chip away at masculine behaviors and attitudes that contribute to the spread of HIV, according to Dr. Peter Piot, Executive Director of the Joint United Nations Programme on HIV/AIDS (UNAIDS).

AIDS Vaccine Enters Clinical Trial

The first AIDS vaccine made at NIAID's vaccine research center enters clinical trials just one year after NIAID's laboratories open. Click here to read more.

Visual AIDS Newsletter Now Online

Visual AIDS' Fall newsletter, Art+, is now live! Read the latest news from this great group for HIV-positive artists.

Harm Reduction, Drug Use and HIV

Much of the work on harm reduction has only been in relation to drug use. This fact sheet from New Mexico AIDS InfoNet focuses on harm reduction methods for HIV as well.

Facts About Acute HIV Infection

It's not easy to identify people with acute HIV infection. Some people have no symptoms and if symptoms do occur, diseases like the flu might be their cause. Read this new fact sheet about acute HIV infection from the New Mexico AIDS InfoNet.

Structured Treatment Interruptions Demystified

"Confused about structured treatment interruptions (STIs)? So am I, and I do this for a living! That's why I pulled Jamie aside to explain that SITs/STIs are not a 'Do It Yourself' course offered at Homo Depot." The facts about STIs, from Positively Aware.

New Director for AIDS Action

AIDS Action announces that Harriet C. (Hattie) Babbitt is taking the helm as the organization's next executive director, effective immediately.

The Drug Development Pipeline

Worried about future HIV drug development? Treatment Action Group has put together a handy chart of all the HIV drugs that are in the development pipeline (including some that were being developed but have been cancelled).

When to Start Treatment Recommendations

David Barr from Treatment Action Group revisits the changes to the federal when-to-start recommendations announced earlier this year. He urges us to consider both the roots and the ramifications of this extraordinary development.

Post-Exposure Prophylaxis

Did you know that the overall transmission rate of HIV infection following occupational exposure is estimated to be approximately 0.3%? Read Seattle Treatment Project's update on how transmission can be avoided with post-exposure prophylaxis.

To read more on post-exposure prophylaxis, browse through The Body's collection of articles.

Boehringer-Ingelheim Provides Viramune Free to Stop Mother-to-Child Transmission

Boehringer-Ingelheim works to make nevirapine available to prevent mother-to-child transmission of HIV, read the details from Seattle Treatment Project.

Web Highlights
A Selection of the Top HIV/AIDS Stories from Across the Internet

How Some Live With AIDS With Little or No Therapy
From The New York Times (free registration required) (October 10, 2001)

AIDS Discrimination Spreading in Asia
From The Times of India (October 10, 2001)

Integrating Primary Medical Care With Addiction Treatment
A Randomized Controlled Trial (October 10, 2001)
From the Journal of American Medical Association

Cultural Taboos Increase Women's HIV Risk
From the BBC News (October 8, 2001)

Patients Warned of Dangers of Chinese Medicines
From the British Medical Journal (October 6, 2001)

Previous Update | Next Update
Back to The Body's HIV/AIDS News Updates main page